flat

DRUG2 trials

Sponsors

Medica Scientia Innovation Research S.L., Medica Scientia Innovation Research S.L., Stemline Therapeutics Inc., University Of Turku

Conditions

ESR1-mutatedProgressive multiple sclerosisadvanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors.patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative

Phase 2

Prospective, randomized, double-blind, placebo-controlled, single-center comparative trial evaluating oral Istradefylline 40 mg once daily for reducing microglial activation in the brain of patients with progressive multiple sclerosis (MS)

RecruitingCTIS2024-517336-21-00

University Of TurkuProgressive multiple sclerosis

Start: 2025-03-31Target: 34Updated: 2025-02-12

Phase 3

A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors - The ADELA study-

RecruitingCTIS2024-512926-27-00

Medica Scientia Innovation Research S.L., Medica Scientia Innovation Research S.L., Stemline Therapeutics Inc.advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors., ESR1-mutated, patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative

Start: 2024-12-12Target: 214Updated: 2025-02-13